{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:42:36Z","timestamp":1776462156476,"version":"3.51.2"},"reference-count":28,"publisher":"Wiley","issue":"18","license":[{"start":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T00:00:00Z","timestamp":1245196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>In patients with chronic\u2010phase chronic myeloid leukemia (CP\u2010CML), imatinib resistance is of increasing importance. Imatinib dose escalation was the main treatment option before dasatinib, which has 325\u2010fold more potent inhibition than imatinib against unmutated Bcr\u2010Abl in vitro. Data with a minimum of 2 years of follow\u2010up were available for the current study of dasatinib and high\u2010dose imatinib in CP\u2010CML resistant to imatinib at daily doses from 400 mg to 600 mg.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>A phase 2, open\u2010label study was initiated of 150 patients with imatinib\u2010resistant CP\u2010CML who were randomized (2:1) to receive either dasatinib 70 mg twice daily (n = 101) or high\u2010dose imatinib 800 mg (400 mg twice daily; n = 49).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>At a minimum follow\u2010up of 2 years, dasatinib demonstrated higher rates of complete hematologic response (93% vs 82%; <jats:italic>P<\/jats:italic> = .034), major cytogenetic response (MCyR) (53% vs 33%; <jats:italic>P<\/jats:italic> = .017), and complete cytogenetic response (44% vs 18%; <jats:italic>P<\/jats:italic> = .0025). At 18 months, the MCyR was maintained in 90% of patients on the dasatinib arm and in 74% of patients on the high\u2010dose imatinib arm. Major molecular response rates also were more frequent with dasatinib than with high\u2010dose imatinib (29% vs 12%; <jats:italic>P<\/jats:italic> = .028). The estimated progression\u2010free survival also favored dasatinib (unstratified log\u2010rank test; <jats:italic>P<\/jats:italic> = .0012).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>After 2 years of follow\u2010up, dasatinib demonstrated durable responses and improved response and progression\u2010free survival rates relative to high\u2010dose imatinib. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24504","type":"journal-article","created":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T18:28:40Z","timestamp":1245263320000},"page":"4136-4147","source":"Crossref","is-referenced-by-count":166,"title":["Dasatinib or high\u2010dose imatinib for chronic\u2010phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily"],"prefix":"10.1002","volume":"115","author":[{"given":"Hagop","family":"Kantarjian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saengsuree","family":"Jootar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Holowiecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson","family":"Hamerschlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Bleickardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dejardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,6,17]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"National Comprehensive Cancer Network Inc. The Chronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology. Version 1.2009. Available athttp:\/\/www.nccn.org. Accessed August 29 2008."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct071828"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2004.03.001"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1451"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-103523"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"313a","DOI":"10.1182\/blood.V110.11.1035.1035","article-title":"Impact of imatinib mesylate dose escalation on resistance and suboptimal responses to standard\u2010dose therapy in patients (pts) with chronic myeloid leukemia (CML) [abstract]","volume":"110","author":"Jabbour E","year":"2007","journal-title":"Blood."},{"key":"e_1_2_6_11_2","first-page":"317a","article-title":"Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML\u2010CP) [abstract]","volume":"110","author":"Kantarjian HM","year":"2007","journal-title":"Blood."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2042"},{"key":"e_1_2_6_13_2","first-page":"2092","article-title":"The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment","volume":"9","author":"Zonder JA","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056028"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"374s","DOI":"10.1200\/jco.2008.26.15_suppl.7009","article-title":"Dasatinib 2\u2010year efficacy in patients with chronic\u2010phase chronic myelogenous leukemia (CML\u2010CP) with resistance or intolerance to imatinib (START\u2010C) [abstract]","volume":"26","author":"Mauro MJ","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2001.00963.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.2307\/2530286"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707243370402"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3097"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24504","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:23:32Z","timestamp":1760268212000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24504"}},"subtitle":["Two\u2010year follow\u2010up of a randomized phase 2 study (START\u2010R)"],"short-title":[],"issued":{"date-parts":[[2009,6,17]]},"references-count":28,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2009,9,15]]}},"alternative-id":["10.1002\/cncr.24504"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24504","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,17]]}}}